Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer

No evidence is available on the head-to-head comparison of clinical outcomes of patients treated with immune checkpoint inhibitors (ICIs) for advanced non-small cell lung cancer (NSCLC) in a real-world setting. We aimed to compare the effectiveness and cost-effectiveness profile of nivolumab, pembro...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Matteo Franchi, Giacomo Pellegrini, Giovanni Corrao
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI AG 2022-04-01
Colecção:Pharmaceuticals
Assuntos:
non-small cell lung cancer
immune checkpoint inhibitors
real-world
effectiveness
cost-effectiveness
Acesso em linha:https://www.mdpi.com/1424-8247/15/4/489
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados